| Q55245159 | 18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. |
| Q111854475 | A Longitudinal Evaluation of Speech Rate in Primary Progressive Apraxia of Speech |
| Q60309357 | Amyloid- and tau-PET imaging in a familial prion kindred |
| Q92488162 | An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant |
| Q90340969 | Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration |
| Q100509978 | Associations of Quantitative Susceptibility Mapping with Alzheimer's Disease Clinical and Imaging Markers |
| Q92628969 | Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants |
| Q90646389 | Cerebral microbleeds: Prevalence and relationship to amyloid burden |
| Q27317202 | Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech |
| Q88810833 | Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration |
| Q98208877 | Communication Limitations in Patients With Progressive Apraxia of Speech and Aphasia |
| Q91684761 | Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum |
| Q91577531 | Corrigendum to "Prosodic and phonetic subtypes of primary progressive apraxia of speech" [Brain Lang. 184 (2018) 54-65] |
| Q55453508 | Disrupted functional connectivity in primary progressive apraxia of speech. |
| Q88053895 | FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis |
| Q89626406 | Longitudinal Amyloid-β PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration |
| Q91922643 | Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech |
| Q94954301 | Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia |
| Q64814750 | MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy |
| Q91675855 | Multimodal neuroimaging relationships in progressive supranuclear palsy |
| Q57175977 | Non-right handed primary progressive apraxia of speech |
| Q33654620 | Nonverbal oral apraxia in primary progressive aphasia and apraxia of speech |
| Q47149897 | Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome |
| Q113178216 | Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET |
| Q100949634 | Predicting future rates of tau accumulation on PET |
| Q92748350 | Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome |
| Q97529257 | Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes |
| Q64960537 | Prosodic and phonetic subtypes of primary progressive apraxia of speech. |
| Q120333336 | Rate Modulation Abilities in Acquired Motor Speech Disorders |
| Q64780605 | Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy |
| Q47987344 | Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum |
| Q50042853 | Tau-negative amnestic dementia masquerading as Alzheimer disease dementia |
| Q90006715 | The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes |
| Q100524052 | The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study |
| Q91010566 | The influence of β-amyloid on [18F]AV-1451 in semantic variant of primary progressive aphasia |
| Q96229271 | Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy |
| Q90873939 | Western Aphasia Battery-Revised Profiles in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech |
| Q49937027 | [18F]AV-1451 tau-PET and primary progressive aphasia |